Brian Buntz is a journalist at Medical Design & Outsourcing. He covers a range of topics within medicine and healthcare, focusing on healthcare technology, artificial intelligence, and machine learning. His work has been featured in notable publications such as TED Conferences, MassDevice, and Pharmaceutical Processing World.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Brian Buntz's articles primarily focus on the healthcare and pharmaceutical industry, with a strong emphasis on data-driven insights. His coverage suggests an interest in topics such as pharmaceutical innovation, M&A activity, emerging trends in drug approvals, and AI applications within healthcare.
Given his reliance on citing data and press releases, Brian may be interested in pitches that provide comprehensive data analysis or newsworthy findings related to pharmaceuticals, medical research advancements, or trends in healthcare technology. Additionally, he might be open to receiving press releases announcing significant developments within the healthcare and pharmaceutical sectors.
While Brian's geographic focus is not specified, his coverage appears to encompass global perspectives on the healthcare and pharmaceutical industry. Therefore, relevant pitches should consider international implications or broader industry trends rather than focusing solely on specific regional matters unless they have global significance.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Brian Buntz
The country has transformed considerably since the 1980s. “Back then, we were a coffee-and-banana country,” Morales said. Both the medical device and semiconductor industries have made significant investments. The medical device firm Baxter set up shop in 1987. Intel followed with a landmark $300-million-plus semiconductor assembly-and-test plant investment announced in late 1996 and begun in…
By: Brian Buntz
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
By: Brian Buntz
This website uses cookies We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
By: Brian Buntz
The U.S. Department of Energy has opened a funding opportunity of up to $12 million for research on space-grade photovoltaic cells, manufacturing processes and testing systems. The Space Photovoltaics Research and Development opportunity is a notable expansion of DOE’s photovoltaic R&D portfolio into spacecraft power after a history centered largely on terrestrial solar applications. “The…
By: Brian Buntz
OpenAI’s new GPT-6 Astra scored 62.7% under the benchmark’s standard, provider-neutral testing harness on ARC-AGI-3, an interactive benchmark that requires AI agents to explore unfamiliar games, infer their rules and goals, and plan effective actions without instructions. The same model scored 99.9% with an OpenAI-specific context-management adapter that preserves the model’s hidden reasoning state between…
By: Brian Buntz
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
By: Brian Buntz
ICON reports roughly 30% shorter cycle times in two clinical-trial workflows as it expands AI agents through Anthropic and Microsoft collaborations. We caught up with senior vice president of enterprise AI at ICON plc to learn more.
By: Brian Buntz
| An image from the RxAlmanac homepage For pharma companies preparing to launch a drug or expand commercial operations, choosing
By: Brian Buntz
AI’s spending boom, which has continued mostly unabated so far in 2026, has left its imprint on many of this year’s world-leading innovators. In pharma, Eli Lilly, Roche and Bristol Myers Squibb have each announced NVIDIA-based AI supercomputers. In the industrial sector, Siemens, for instance, is developing an “Industrial AI Operating System.” In…
By: Brian Buntz
While 84% of R&D leaders expect generative AI to deliver significant benefits for their functions, 60% concede that their current integrations fall short of expectations. This gap is a result of how R&D organizations are choosing to deploy GenAI rather than the technology itself. R&D organizations typically rely on a traditional technology adoption playbook, treating…
